Invention Grant
- Patent Title: Anti-prokineticin receptor (PROKR) antibodies and uses thereof
-
Application No.: US14678347Application Date: 2015-04-03
-
Publication No.: US09951132B2Publication Date: 2018-04-24
- Inventor: Lynn Macdonald , Michael L. LaCroix-Fralish
- Applicant: Regeneron Pharmaceuticals, Inc.
- Applicant Address: US NY Tarrytown
- Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee: Regeneron Pharmaceuticals, Inc.
- Current Assignee Address: US NY Tarrytown
- Agency: Swanson & Bratschun, L.L.C.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/28 ; A61K39/00
Abstract:
The present invention provides antibodies that bind to prokineticin receptors (PROKRs) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PROKR1 and/or PROKR2. The present invention includes antibodies that bind cell surface-expressed PROKR1 and/or PROKR2. In certain embodiments, the antibodies of the present invention are capable of blocking prokineticin (PK)-mediated activation of one or more PROKR. The antibodies of the invention are useful for the treatment of various diseases and disorders mediated by prokineticin signaling.
Public/Granted literature
- US20150266957A1 Anti-Prokineticin Receptor (PROKR) Antibodies and Uses Thereof Public/Granted day:2015-09-24
Information query
